Results for the Financial Year Ended March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fabino Enterprises Ltd (formerly Fabino Life Sciences Ltd), listed on BSE SME platform (Scrip Code: 543444), reported audited results for FY25. On a standalone basis, revenue from operations jumped sharply to Rs 1,803.60 lakhs from Rs 608.41 lakhs in FY24, while net profit rose to Rs 13.19 lakhs from Rs 4.76 lakhs, with EPS of Rs 0.63 vs Rs 0.23. On a consolidated basis (including subsidiary Upender Metaplast Pvt Ltd), revenue from operations actually declined to Rs 1,803.60 lakhs from Rs 2,108.28 lakhs in FY24, but net profit still rose to Rs 6.11 lakhs from Rs 3.58 lakhs, aided by other income of Rs 729.63 lakhs. The auditor (DGMS & Co) issued an unmodified opinion on both results. The Board also appointed new Secretarial and Internal Auditors for FY26 and FY27, and accepted the resignation of Company Secretary Ms. Kanchi Gehlot.
Shareholders should note the strong standalone growth story (revenue nearly tripled, PAT nearly tripled), but the consolidated picture is mixed with declining core revenue and the PAT rise relying on a large one-time other income. Standalone operating cash flow turned negative (-Rs 12.26 lakhs), signalling working capital strain from sharply higher trade receivables and borrowings (long-term debt nearly doubled to Rs 161.23 lakhs). The clean audit opinion is positive, but the auditor changes and Company Secretary exit are minor governance items to watch.